Holen Sie sich die Stockscreener-App
472.21
3.52%
-17.21
Vorhandelsmarkt:
472.22
0.01
+0.00%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt UTHR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$489.42
Offen:
$472.72
24-Stunden-Volumen:
545.30K
Relative Volume:
1.06
Marktkapitalisierung:
$20.25B
Einnahmen:
$3.17B
Nettoeinkommen (Verlust:
$1.29B
KGV:
17.43
EPS:
27.0947
Netto-Cashflow:
$1.01B
1W Leistung:
-5.04%
1M Leistung:
-7.93%
6M Leistung:
-11.21%
1J Leistung:
+7.63%
1-Tages-Spanne:
$468.97
$481.32
1-Wochen-Bereich:
$468.97
$500.05
52-Wochen-Spanne:
$409.07
$609.35
United Therapeutics Corp Stock (UTHR) Company Profile
Firmenname
United Therapeutics Corp
Sektor
Telefon
(301) 608-9292
Adresse
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR vs TAK, TEVA, HLN, ZTS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
472.21 | 20.25B | 3.17B | 1.29B | 1.01B | 27.09 |
TAK
Takeda Pharmaceutical Co Adr
|
18.59 | 59.37B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
40.22 | 46.91B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.22 | 40.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
70.27 | 29.04B | 9.51B | 2.64B | 2.14B | 6.0361 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-10 | Eingeleitet | Raymond James | Outperform |
| 2025-10-20 | Eingeleitet | Wells Fargo | Underweight |
| 2025-09-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-06-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-04-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-04-21 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2024-07-11 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-12 | Hochstufung | Goldman | Sell → Neutral |
| 2024-02-05 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2022-12-06 | Eingeleitet | UBS | Buy |
| 2022-12-05 | Eingeleitet | Goldman | Sell |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-09-20 | Bestätigt | BofA Securities | Underperform |
| 2022-09-19 | Fortgesetzt | Wedbush | Outperform |
| 2022-02-11 | Eingeleitet | BTIG Research | Neutral |
| 2021-07-14 | Hochstufung | Argus | Hold → Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-02-01 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
| 2020-06-25 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-03-10 | Hochstufung | Jefferies | Hold → Buy |
| 2020-02-27 | Hochstufung | Cowen | Market Perform → Outperform |
| 2020-01-31 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-12-03 | Eingeleitet | BofA/Merrill | Underperform |
| 2019-08-01 | Hochstufung | Jefferies | Underperform → Hold |
| 2019-08-01 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2019-07-01 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-05-17 | Hochstufung | UBS | Sell → Neutral |
| 2019-05-09 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2018-10-12 | Hochstufung | Standpoint Research | Hold → Buy |
| 2018-08-08 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2018-04-03 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2018-02-22 | Bestätigt | Barclays | Underweight |
| 2018-01-18 | Fortgesetzt | Credit Suisse | Underperform |
| 2017-12-27 | Bestätigt | Wedbush | Outperform |
| 2017-04-27 | Bestätigt | Wedbush | Outperform |
| 2017-03-30 | Eingeleitet | UBS | Sell |
| 2017-03-16 | Eingeleitet | Credit Suisse | Underperform |
Alle ansehen
United Therapeutics Corp Aktie (UTHR) Neueste Nachrichten
Why United Therapeutics (UTHR) Shares Are Falling Today - finance.yahoo.com
A Look at United Therapeutics Corp (UTHR) After 3.5% Decline -- GF Value $427.97 vs Price $472.21 - GuruFocus
United Therapeutics CEO Rothblatt sells $4.67m in stock after option exercise - Investing.com
Form 4 United Therapeutics Corporation For: 24 September - Investing.com India
After exercising 9,500 options, family trusts sold United Therapeutics (UTHR) shares under a pre-arranged plan. - Stock Titan
United Therapeutics Falls as Goldman Sachs Sets $321 Price Target - citybiz
United Therapeutics Corporation (UTHR) stock price, news, quote and history - Yahoo Finance UK
United Therapeutics, Sagimet drop as Goldman issues Sell (UTHR) - Seeking Alpha
United Therapeutics (NASDAQ:UTHR): A Growth-at-a-Reasonable-Price Candidate - ChartMill
Goldman Sachs initiates United Therapeutics stock with sell rating - Investing.com
Under a pre-arranged plan, United Therapeutics (UTHR) CEO’s family trusts exercise 9,500 options and sell the shares. - Stock Titan
United Therapeutics: Strong Catalyst Flow Bodes Well For Near-Term Growth (NASDAQ:UTHR) - Seeking Alpha
United Therapeutics Corporation at Bernstein Healthcare Forum Transcript - GuruFocus
United Therapeutics CEO Rothblatt sells $4.7m in stock By Investing.com - Investing.com Australia
United Therapeutics CEO Rothblatt sells $4.7m in stock - Investing.com
United Therapeutics (UTHR) CEO sells shares at nearly $500 each - Stock Titan
United Therapeutics CEO Rothblatt sells $4.7m in UTHR shares By Investing.com - Investing.com Nigeria
Form 4 United Therapeutics Corporation For: 22 September By Investing.com - Investing.com Canada
United Therapeutics CEO Rothblatt sells $4.7m in UTHR shares - Investing.com
CEO stock sale near $500 a share was preplanned, United Therapeutics (UTHR) says - Stock Titan
United Therapeutics (NASDAQ:UTHR) Screens as a High-Quality, Debt-Free Stock - ChartMill
United Therapeutics EVP Paul A. Mahon Executes Stock Options and Sells Shares Under 10b5-1 Plan - kalkinemedia.com
United Therapeutics (UTHR) CEO sells 9,500 shares under preset plan - Stock Titan
United Therapeutics (NASDAQ: UTHR) general counsel sells shares near $500 - Stock Titan
United Therapeutics (NASDAQ: UTHR) CEO exercises 9,500 options and sells matching shares - Stock Titan
United Therapeutics (NASDAQ: UTHR) CEO exercises options and sells stock under preset plan - Stock Titan
Director Nilda Mesa Sells 228 Shares of United Therapeutics Corp (UTHR) - GuruFocus
United Therapeutics (NASDAQ: UTHR) CEO exercises 9,500 options, then sells the shares under preset plan - Stock Titan
United Therapeutics (UTHR) director exercises options, then sells shares - Stock Titan
United Therapeutics CEO Martine Rothblatt sells $4.7m in shares By Investing.com - Investing.com Nigeria
United Therapeutics Corporation at Morgan Stanley Global Healthcare Conference Transcript - GuruFocus
United Therapeutics CEO Martine Rothblatt sells $4.7m in shares - Investing.com
United Therapeutics (UTHR) CEO exercises options, sells 9,500 shares - Stock Titan
LQDA Loses 13.9% in a Month: Should Investors Avoid the Stock Now? - Zacks Investment Research
United Therapeutics (UTHR) Sets $477.6 Million Buyback. Can Pipeline Funding Keep Pace? - Yahoo Finance
Rothblatt Executes Stock Option Exercise and Multiple Share Sales Under 10b5-1 Plan at United Therapeutics - kalkinemedia.com
United Therapeutics (UTHR) CEO sells 9,500 shares under 10b5-1 plan - Stock Titan
United Therapeutics CEO Martine Rothblatt sells $4.7m in stock By Investing.com - Investing.com Australia
United Therapeutics at Cantor healthcare conference: fibrosis push widens By Investing.com - Investing.com Australia
United Therapeutics CEO Martine Rothblatt sells $4.7m in stock - investing.com
United Therapeutics (UTHR) CEO exercises options and sells 9,500 shares in preset plan - Stock Titan
United Therapeutics Launches $477.6M Accelerated Share Buyback - Minichart
United Therapeutics Launches $477.6 Million Accelerated Share Repurchase With Citi - TradingView
United Therapeutics (UTHR) moves to return $4B to shareholders with new buyback - Stock Titan
United Therapeutics (UTHR) CEO sells 9,500 shares under preset trading plan - Stock Titan
United Therapeutics Corporation at Wells Fargo Healthcare Conference Transcript - GuruFocus
United Therapeutics Corporation Announces Accelerated Share Repurchase Agreement for Remainder of $2.0 Billion Authorization - marketscreener.com
United Therapeutics Corporation (UTHR) Stock Analysis: Insights on a 36.24% Potential Upside - DirectorsTalk Interviews
United Therapeutics (NASDAQ: UTHR) CEO sells 9,500 shares under 10b5-1 plan - Stock Titan
MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’ - Stocktwits
United Therapeutics (UTHR) Down 8% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Finanzdaten der United Therapeutics Corp-Aktie (UTHR)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.75%
0.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):